China Pharmaceutical (CPHI) Launching Sanitizer Cleaner for Coronavirus


(NEW YORK)–China Pharmaceutical Holdings Limited (NYSE: CPHI), announced it subsidiary, Hainan Helpson Pharmaceutical & Biotechnology Co., Ltd. (“Helpson”) has launched a new wash-free sanitizer cleanser in response to coronavirus outbreak.

In response to China’s call to combat the novel coronavirus Helpson has leveraged the advantages of its pharmaceutical production facilities to launch its new sterilization product, which has received production approval from the health authority, and is in production process.

Delivery of this new sanitizer cleaner is expected to come to market shortly.

Chart Analysis

Ludlow Research made note to its subscribers that with a market cap around $38 million, and float of only around 28 million shares, the strong demand fro coronavirus stocks and set up on chart technicals could position CPHI for potential run to $2.00+ short-term as news of their disinfection cleaner are released.

Other Viral and Anti-infection Products

Roxithromycin Dispersible Tablets: Pharyngitis and tonsillitis caused by Streptococcus pyogenes; sinusitis, tympanitis, acute and chronic bronchitis caused by acute bacterial infection, Mycoplasma pneumonia and Chlamydia pneumoniae; urethritis and cervical infection caused by chlamydia trachomatis; skin soft tissue infection caused by sensitive bacteria.

Clarithromycin Granules and Capsules: Nasopharynx infection, lower respiratory tract infection, skin tissue infection, acute tympanitis and mycoplasma pneumonia caused by clarithromycin susceptible organisms; urethritis and cervical infection caused by chlamydia trachomatis; and the treatment of legionella infection, mycobacterium avium complex (MAC) infection and helicobacter pylori infection.

Naproxen Sodium and PseudophedrineHydrochlorida Sustained Release Tablet: Relieves cold, sinus and flu symptoms, blocked nose caused by anaphylaxis rhinitis, runny nose, fever, sore throat, symptoms of myalgia in the limbs and pain around the joints.

Register to Coronavirus Stock Updates

Coronavirus stocks have been one of the hottest sector in 2020 and you can receive updates on these stocks by registering to our free online newsletter for updates

INO – Inovio Pharmaceutica
CODX – Co-Diagnostics
OPK – OPKO Healthls
APT – Alpha Pro Tech
NNVC – NanoViricides
CBLI – Cleveland Biolabs
LLIT – Lianluo Smart
AEMD – Aethlon Medical

About China Pharma Holdings, Inc.

China Pharma Holdings, Inc. is a specialty pharmaceutical company that develops, manufactures and markets a diversified portfolio of products, focusing on conditions with high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company’s cost-effective business model is driven by market demand and supported by new GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding nationwide distribution network across all major cities and provinces in China. The Company’s wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province. For more information about China Pharma Holdings, Inc., please visit The Company routinely posts important information on its website.

This is NOT a solicitation to Buy or Sell any security, but rather is for informational purposes only. Content contained herein includes facts, views, opinions and recommendations of individuals and organizations deemed of interest. Wall Street Newscast (“WSNC”) does not guarantee the accuracy, completeness or timeliness of, or otherwise endorse these views, opinions or recommendations, or give investment advice. In Compliance with SEC Rule 17B WSNC was not compensated for this media alert. WSNC, or any of its affiliates, hold no positions in securities mentioned above. These investments may involve a high degree of risk, thus investors are highly encouraged to consult with a financial adviser before any and all investments.

Safe Harbor Statements:
This website includes statements that may constitute forward-looking statements made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Although the Company believes that the expectations reflected in such forward-looking statements are based on reasonable assumptions, such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected.
High Risk
Small and Micro cap, or ‘penny stocks’, involve a high degree of risk, and we highly encourage investors to consult with a financial adviser before making any and all investment decisions when investing in these type of securities